姜黄素-胡椒碱联合补充对COVID-19门诊患者临床症状、持续时间、严重程度及炎症因子的疗效:一项随机双盲安慰剂对照试验
该随机双盲安慰剂对照试验纳入46例COVID-19门诊患者,随机接受姜黄素-胡椒碱联合补充(每粒胶囊含500 mg姜黄素+5 mg胡椒碱,每日2粒)或安慰剂,为期14天。结果显示两组在血常规、肝酶、血糖、血脂、肾功能及C反应蛋白(CRP)的平均变化上无显著差异;第2周两组健康状态(干咳、咳痰、寒战、咽痛、乏力、肌肉疼痛、头痛、呼吸困难)均显著改善(P值<0.05),但乏力改善在姜黄素-胡椒碱组优于安慰剂组(P值025)。结论认为姜黄素-胡椒碱联合补充可显著减轻乏力,但对其他生化及临床指标无显著影响。
要点
- 姜黄素-胡椒碱联合补充可显著改善COVID-19门诊患者的乏力症状(P值025)。
- 两组血常规、肝酶、血糖、血脂、肾功能及CRP的平均变化无显著差异。
- 第2周两组多项症状均显著改善(P值<0.05),但仅乏力改善组间有差异。
核心结论
- 姜黄素-胡椒碱联合补充可显著减轻COVID-19门诊患者的乏力症状。
- 姜黄素-胡椒碱联合补充对其他生化及临床指标无显著影响。
研究设计与样本
- 随机双盲安慰剂对照试验,纳入46例COVID-19门诊患者。
- 干预组接受姜黄素-胡椒碱胶囊(每粒含500 mg姜黄素+5 mg胡椒碱),每次2粒,为期14天;对照组接受安慰剂。
主要发现
- 两组血常规、肝酶、血糖、血脂、肾功能及CRP的平均变化无显著差异。
- 第2周两组干咳、咳痰、寒战、咽痛、乏力、肌肉疼痛、头痛及呼吸困难均显著改善(P值<0.05)。
- 乏力改善在姜黄素-胡椒碱组优于安慰剂组(P值025)。
局限性
- 原文未报告局限性。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
BACKGROUND: COVID-19 pandemic has made the disease a major global problem by creating a significant burden on health, economic, and social status. To date, there are no effective and approved medications for this disease. Curcumin as an anti-inflammatory agent can have a positive effect on the control of COVID-19 complications. This study aimed to assess the efficacy of curcumin-piperine supplementation on clinical symptoms, duration, severity, and inflammatory factors in patients with COVID-19. METHODS: Forty-six outpatients with COVID-19 disease were randomly allocated to receive two capsules of curcumin-piperine; each capsule contained 500 mg curcumin plus 5 mg piperine or placebo for 14 days. RESULTS: Mean changes in complete blood count, liver enzymes, blood glucose levels, lipid parameters, kidney function, and c-reactive protein (CRP) were not significantly different between the two groups. There was a significant improvement in health status, including dry cough, sputum cough, ague, sore throat, weakness, muscular pain, headache, and dyspnea at week 2 in both curcumin-piperine and placebo groups (P value < 0.05); however, the improvement in weakness was more in the curcumin-piperine group than with placebo group (P value 025). CONCLUSION: The present study results showed that curcumin-piperine co-supplementation in outpatients with COVID-19 could significantly reduce weakness. However, in this study, curcumin-piperine co-supplementation could not significantly affect the other indices, including biochemical and clinical indices. TRIAL REGISTRATION: Iranian Registry of Clinical Trials IRCT20121216011763N46 . 2020-10-31.
引用
- Askari G, Sahebkar A, Soleimani D, et al. The efficacy of curcumin-piperine co-supplementation on clinical symptoms, duration, severity, and inflammatory factors in COVID-19 outpatients: a randomized double-blind, placebo-controlled trial. Trials. 2022. PMID: 35668500. doi:10.1186/s13063-022-06375-w
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。